Chiasma Inc

Chiasma — Corporate Update (August 2017)

12 slides from Chiasma's corporate update, Aug 10, 2017

  1. Slide 1: Chiasma, Inc. Regulatory update call

    Chiasma, Inc. Regulatory update call August 10, 2017 NASDAQ: CHMA Exhibit 99.3

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are i

  3. Slide 3: Announced SPA Agreement

    Announced SPA Agreement Reached agreement with FDA on design of new Phase 3 trial (OPTIMAL) for octreotide capsules, conditionally trade-named Mycapssa® Agreed-upon study is designed to address FDA’s concerns raised in the Complete Response Letter from April 2016 Provides regulatory clarity of clini

  4. Slide 4: Company Overview

    Company Overview Focus: Improving the lives of patients with rare and serious chronic diseases Approximately $80.1M in cash and investments as of June 30, 2017; believed sufficient to reach anticipated release of Phase 3 OPTIMAL study top-line data by the end of 2019, while conducting MPOWERED in pa

  5. Slide 5: Mycapssa (octreotide capsules) for Acromegaly

    Mycapssa® (octreotide capsules) for Acromegaly Rare disease caused by excessive secretion of growth hormone (GH) stemming from a benign pituitary tumor that leads to excess of insulin-like growth factor-1 (IGF-1) 69,000(1) patients worldwide Symptoms include enlarged hands, feet and internal organs,

  6. Slide 6: Current Injection Therapies Carry Treatment Burdens

    Current Injection Therapies Carry Treatment Burdens(1) intramuscular Novartis’ Octreotide LAR: 19 or 20 Gauge Ipsen’s Lanreotide Depot: 18 or 19 Gauge deep subcutaneous Emotional Impact 36% feel loss of independence due to chronic injections Injection Site Reactions Hardness (48%), nodules (38%), sw

  7. Slide 7: OPTIMAL - Octreotide capsules versus Placebo Treatment In MultinationAL centers

    OPTIMAL - Octreotide capsules versus Placebo Treatment In MultinationAL centers; New Phase 3 SPA Agreement with FDA New Phase 3 trial will be a randomized, double-blind, placebo-controlled study and is expected to enroll 50 adult acromegaly patients Treatment duration of nine months At least 20% of

  8. Slide 8: OPTIMAL trial design

    OPTIMAL - Octreotide capsules versus Placebo Treatment In MultinationAL centers Last Injection Open Label Extension Double-blind placebo-controlled (DPC) Period 36 weeks Eligibility criteria: Average IGF-1 ≤ 1.0 ´ ULN Confirmation active disease (IGF-1≥1.3xULN post last surgery) Screening (≤ 8 weeks

  9. Slide 9: Ongoing Phase 3 Trial; Design Accepted by EMA

    Ongoing Phase 3 Trial; Design Accepted by EMA How does the sustained response compare on oral vs. injection? Key study questions: How do acromegaly symptoms compare on oral vs. injection? How does quality of life compare on oral vs. injection? Last Injection Day (-28) Screening First Dose 6-Month Ru

  10. Slide 10: Chiasma Financial Update

    Chiasma Financial Update $80.1M in cash and investments as of June 30, 2017 Cash burn of $13M in H1:2017 Total direct cost of OPTIMAL projected at between $18M and $20M Remaining direct cost of MPOWERED projected at between $15M and $17M Expect cash balance of >$60M at December 31, 2017 Based on cur

  11. Slide 11: Mycapssa – Regulatory Clarity in U.S.

    Mycapssa – Regulatory Clarity in U.S. Optimistic about the path forward for Mycapssa® SPA agreement with FDA a significant milestone for Chiasma Clears way for new Phase 3 study; expected to result in resubmission of NDA OPTIMAL clinical trial material (Placebo and Mycapssa) is ready for initiation

  12. Slide 12: Thank You

    Thank You August 10, 2017 NASDAQ: CHMA

Chiasma — Corporate Update (August 2017) on 6ix